Cencora, Inc.

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cencora, Inc. and other ETFs, options, and stocks.

About COR

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments. 

CEO
Robert P. Mauch
CEORobert P. Mauch
Employees
51,000
Employees51,000
Headquarters
Conshohocken, Pennsylvania
HeadquartersConshohocken, Pennsylvania
Founded
1947
Founded1947
Employees
51,000
Employees51,000

COR Key Statistics

Market cap
61.35B
Market cap61.35B
Price-Earnings ratio
23.86
Price-Earnings ratio23.86
Dividend yield
0.75%
Dividend yield0.75%
Average volume
1.29M
Average volume1.29M
High today
$325.13
High today$325.13
Low today
$317.96
Low today$317.96
Open price
$322.36
Open price$322.36
Volume
790.60K
Volume790.60K
52 Week high
$377.54
52 Week high$377.54
52 Week low
$244.82
52 Week low$244.82

Stock Snapshot

As of today, Cencora, Inc.(COR) shares are valued at $321.57. The company's market cap stands at 61.35B, with a P/E ratio of 23.86 and a dividend yield of 0.75%.

As of 2026-09-11, Cencora, Inc.(COR) stock has fluctuated between $317.96 and $325.13. The current price stands at $321.57, placing the stock +1.1% above today's low and -1.1% off the high.

Cencora, Inc.(COR) shares are trading with a volume of 790.6K, against a daily average of 1.29M.

In the last year, Cencora, Inc.(COR) shares hit a 52-week high of $377.54 and a 52-week low of $244.82.

In the last year, Cencora, Inc.(COR) shares hit a 52-week high of $377.54 and a 52-week low of $244.82.

COR News

Benzinga 2h
$1000 Invested In Cencora 10 Years Ago Would Be Worth This Much Today - Benzinga

...

$1000 Invested In Cencora 10 Years Ago Would Be Worth This Much Today - Benzinga
Simply Wall St 6d
Why Cencora Is Getting Attention Today

Cencora (COR) stock is in focus after third quarter fiscal 2026 adjusted earnings per share of US$4.48 topped estimates, and the company raised its full year ad...

Why Cencora Is Getting Attention Today
Simply Wall St 7d
Cencora’s New Cell and Gene Services Might Change The Case For Investing In Cencora

Cencora recently launched its Cell and Gene Therapy Enablement service through Accelerate Pharmacy Solutions, aiming to help health systems evaluate, build and...

Cencora’s New Cell and Gene Services Might Change The Case For Investing In Cencora

Analyst ratings

63%

of 19 ratings
Buy
63.2%
Hold
36.8%
Sell
0%

People also own

Based on the portfolios of people who own COR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.